Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Nuvectis Pharma, Inc. - Common Stock (NQ: NVCT ) 6.410 -1.060 (-14.19%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Nuvectis Pharma, Inc. - Common Stock < Previous 1 2 3 4 Next > 12 Health Care Stocks Moving In Tuesday's Intraday Session October 17, 2023 Via Benzinga Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation September 25, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900 September 21, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma: Q1 Earnings Insights May 10, 2023 Via Benzinga Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial September 12, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900 September 06, 2023 Virtual Event to be held on Thursday, September 14, 2023 at 10:00 a.m. ET From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma Announces Participation at Upcoming Investor Conferences September 01, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma August 17, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire 10 Short Squeeze Stocks To Watch: Blue Apron, Intuitive Machines, Yellow Corp, Getty Images And More August 14, 2023 Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a new focus of traders looking for the next huge move. High short interest and steep borrowing costs are among... Via Benzinga Insiders Buying Texas Capital Bancshares And 3 Other Stocks July 28, 2023 Although U.S. stocks closed lower on Thursday, there were a few notable insider trades. Via Benzinga Insiders Buying Steel Connect And 2 Other Stocks July 21, 2023 Although US stocks closed mixed on Thursday, there were a few notable insider trades. Via Benzinga Insiders Buying Nuvectis Pharma And 2 Other Stocks July 20, 2023 Although US stocks closed mostly higher on Wednesday, there were a few notable insider trades. Via Benzinga Insiders Buying Joint Corp And 2 Other Stocks July 19, 2023 Although US stocks closed higher on Tuesday, there were a few notable insider trades. Via Benzinga Insiders Buying BranchOut Food And 2 Other Stocks July 14, 2023 Although US stocks closed higher for the fourth session in a row, there were a few notable insider trades. Via Benzinga Insiders Buying Asana And 2 Other Stocks July 13, 2023 When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.... Via Benzinga More Than $3M Bet On Asana? Check Out These 3 Stocks Insiders Are Buying July 11, 2023 Although US stocks closed higher on Monday, there were a few notable insider trades. Via Benzinga $1M Bet On Children's Place? Check Out These 3 Stocks Insiders Are Buying July 07, 2023 Although US stocks closed lower on Thursday, there were a few notable insider trades. Via Benzinga Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes June 20, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Over $2M Bet On This Financial Services Stock? Check Out These 3 Stocks Insiders Are Buying June 20, 2023 Although US stocks closed lower on Friday, there were a few notable insider trades. Via Benzinga Nuvectis Pharma Announces FDA Clearance of NXP900 IND May 15, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference April 27, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference April 27, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research (“AACR”) Annual Meeting April 18, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma April 10, 2023 Phase 1b study builds on highly consistent preclinical and Phase 1a data From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting March 17, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference March 10, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress February 23, 2023 Treatment with NXP800 resulted in substantial tumor growth inhibition in two in vivo xenograft models of ARID1a-mutated ovarian carcinoma, superior to treatment with cisplatin From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States January 04, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma December 01, 2022 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference October 03, 2022 From Nuvectis Pharma, Inc. Via GlobeNewswire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
